Arkolith/Insider Trading/ZYNE/Form 4

Rosenberger Brian

VP, Commercial & Business Dev.Zynerba Pharmaceuticals, Inc. (ZYNE) · full profile →Form 4 · filed Feb 2, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 1, 2023Tax withholding(F)5K$0.60$3K224K
Jan 31, 2023Grant(A)14K——229K

Transaction Codes

F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-23-003729) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML